| Kimberly Theresa Mcclintock-walla, NP | |
|
67 S Main St, Pearl River, NY 10965-2444 | |
| (845) 368-0800 | |
| (845) 368-0810 |
| Full Name | Kimberly Theresa Mcclintock-walla |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Adult Health |
| Location | 67 S Main St, Pearl River, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750163705 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208VP0000X | Pain Medicine - Pain Medicine | 311577 (New York) | Secondary |
| 363LA2200X | Nurse Practitioner - Adult Health | 311577 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly Theresa Mcclintock-walla, NP 67 S Main St, Pearl River, NY 10965-2444 Ph: (845) 368-0800 | Kimberly Theresa Mcclintock-walla, NP 67 S Main St, Pearl River, NY 10965-2444 Ph: (845) 368-0800 |
News Archive
Kenneth Longmuir, associate professor of physiology & biophysics, and Richard Robertson, professor of anatomy & neurobiology, used liposomes, small spheres (less-than 100 nanometer in diameter) of naturally-occurring lipid molecules, as "packages" for the cancer chemotherapeutic agent doxorubicin, and a small peptide molecule to "address" the package to the targeted tissue.
In an article published in the March issue of the Journal of Cardiovascular Pharmacology and Therapeutics, researchers from Florida Atlantic University (FAU) assess the totality of evidence, including strengths and limitations of different types of evidence contributing to the debate about cardiovascular disease (CVD) risks of cyclooxygenase-2 (COX-2) inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs).
Peripartum cardiomyopathy (PPCM) is a rare disorder characterized by weakened pumping of the heart, or "left ventricular dysfunction," which results in otherwise healthy pregnant women experiencing heart failure shortly before or up to five months after they deliver healthy babies. Despite the seriousness of this condition, a new study published in the Canadian Journal of Cardiology revealed that no significant research has been undertaken to explore how to prevent or treat this disorder.
Haemonetics Corporation, a global blood management solutions company, today announced that it has entered into a reagent development and supply agreement with Quotient Biodiagnostics Group and its wholly owned subsidiary Alba Bioscience Limited. This arrangement provides Haemonetics with exclusive access to Alba's comprehensive catalogue of approved reagents for use in connection with the commercialization of its Arryx laser based blood typing platform.
› Verified 3 days ago